Navigation Links
EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy
Date:7/5/2011

In the first phase III study to include Western lung cancer patients, first-line treatment with erlotinib (Tarceva) nearly doubled progression-free survival compared with chemotherapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).

Erlotinib is a tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR). Non-small cell lung cancer (NSCLC) patients with EGFR activating mutations tend to respond well to TKI therapy.

"Although a growing body of evidence has been emerging about this type of lung cancer, almost all of the studies have been conducted in Asian patients, a group that historically has had significantly different results to NSCLC therapy compared to Western populations," said principal investigator Dr. Radj Gervais, M.D., of the Centre Franois Baclesse in Caen, France. "EURTAC is the first Phase III study with first-line erlotinib in Western patients with this genetically distinct type of advanced NSCLC."

Researchers tested more than 1,000 patients over a five-year-period to find the study population of 174 patients, which were randomly assigned to receive erlotinib or platinum-based chemotherapy.

The response rate to erlotinib was 54.5%, compared with 10.5% to chemotherapy, according to preliminary results. Progression-free survival in the erlotinib arm was 9.4 months, compared with 5.2 months in the chemotherapy arm. Median survival was 22.9 months in the erlotinib arm and 18.8 months in the chemotherapy arm.

"Our results showed that first-line erlotinib nearly doubled progression-free survival; that's a significant improvement over chemotherapy, with a better tolerability profile," Dr. Gervais said. "We now have results for the use of first-line erlotinib in Asian and Western EGFR mutation-positive patients with NSCLC, and so we can carry this knowledge into our daily practice. I think EURTAC really is a big step towards individualized lung cancer care."


'/>"/>

Contact: Rene McGaw
renee.mcgaw@ucdenver.edu
31-205-493-413
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
2. New High Purity Immunoglobulin Enters Phase III in Europe and the US
3. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
4. Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial
5. Askthedoctor.com Makes Medical Information More Accessible to the Public by Completing Phase 1 of US Expansion
6. Intellicate Announces New “Phased Return to Work” (PRtW) Service
7. Southampton scientists begin Phase II patient trial for new asthma treatment
8. Pilot Testing Phase Ends; Expansion Of Sales Force Begins
9. New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
10. Phase II study of an oral therapy for Gaucher disease yields positive results
11. Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... GA (PRWEB) , ... February 08, 2016 , ... Coast ... cavity-free. February is National Children’s Dental Health Month and family dentist Yvonne Dorrian, DMD, ... p.m. at Coast Dental , located next to Target at 1207 North Peachtree ...
(Date:2/8/2016)... ... 08, 2016 , ... The Valentine’s Season is famous for gift giving with flowers, chocolates and ... are loved. This year, for more than 5.6 million Americans suffering with Alzheimer’s, those ... enough to remind them of the lives they’ve led and the people they’ve touched. ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... case packer for pouches, bags, and flow wrapped products at WestPack 2015, February ... specialty product manufacturers step up to semi-automatic or fully-automatic case packing with a ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... expansion into Canada to provide its range of unique and advantaged protective ... Quebec City that will provide bilingual customer service and marketing support. A new ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Bell Agency, ... the latest beneficiary of their ongoing community enrichment program. The current campaign fundraises ... schools. Donations are now being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016 Cardiovascular Surgery Devices - Medical ... Medical Devices sector report, "Cardiovascular Surgery Devices - ... of Cardiovascular Surgery Devices currently in pipeline stage. ... The report provides comprehensive information on the pipeline ... various stages of development. The report reviews major ...
(Date:2/8/2016)... TOKYO and FAIRFIELD, N.J. ... (Otsuka) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that ... exclusive development and commercialization rights for OPA-15406 in the ... agreement also provides manufacturing rights.  OPA-15406 is a topical, ... for atopic dermatitis. --> ...
(Date:2/8/2016)... February 8, 2016 --> ... research report "Ablation Technologies Market by Product (Radiofrequency, Ultrasound, ... Management, Cosmetic Surgery, Ophthalmology, Gynecology) - Global Forecasts to ... market over the forecast period of 2015 to 2020. ... 2020, at CAGR of 10.5% from 2015 to 2020. ...
Breaking Medicine Technology: